Acute or subacute psychiatric change that is new for the patient should prompt consideration of an organic cause, and autoimmune encephalitis is a core diagnostic possibility when psychiatric symptoms appear with certain neurological or systemic features. Expert consensus led by Francesc Graus of Hospital del Mar Research Institute emphasizes that clinicians consider autoimmune causes when there is a rapid (weeks to a few months) development of cognitive deficits, altered consciousness, or prominent behavioral change rather than a long-standing primary psychiatric illness. Early suspicion shortens diagnostic delay and improves outcomes because many autoimmune encephalitides respond to immunotherapy.
Clinical red flags
Key warning signs include the combination of acute or subacute psychosis with new neurological phenomena such as seizures, movement disorders, autonomic instability, or decreased level of consciousness. Laboratory and investigation clues strengthen suspicion: cerebrospinal fluid pleocytosis, new inflammatory changes on brain MRI, or an encephalopathic electroencephalogram. Josep Dalmau of the University of Pennsylvania describes the anti-NMDA receptor syndrome as a paradigmatic example, where young patients—often women—present initially with psychiatric symptoms that rapidly evolve to include movement abnormalities, autonomic features, and reduced responsiveness. Absence of fever or overt infection does not exclude an autoimmune process.
Diagnostic and management implications
When these features appear, clinicians should broaden the workup beyond routine psychiatric evaluation. This includes urgent neurological assessment, cerebrospinal fluid analysis, brain MRI, EEG, and targeted neuronal antibody testing alongside tumor screening when clinically indicated. The consensus criteria from the international group led by Francesc Graus provide a structured approach to identifying probable autoimmune encephalitis based on symptom chronology plus objective neurological or paraclinical findings. Early empirical immunotherapy may be justified in high-probability cases because observational studies and expert experience indicate improved recovery with prompt treatment, while diagnostic delays are associated with worse functional outcomes. Cultural and territorial factors influence presentation and access to diagnostics; for example, tumor-associated cases require context-sensitive screening strategies and follow-up in regions where imaging resources differ. Not every first-episode psychosis is autoimmune, but the coexistence of rapid neurological decline, abnormal paraclinical tests, or refractory symptoms should raise a high index of suspicion and trigger neurological evaluation and appropriate immunological testing.